• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Bayer's Eylea shows pandemic resilience, but major China price cut drags on business

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 05, 2020 at 12:42: AM
via Like many of its peers, Bayer was hurt by pandemic-related business slowdowns last quarter. As patients canceled or postponed doctor’s visits and non-urgent treatments during COVID-19, the company suffered from declines in its women’s health and ophthalmology departments. And the situation was only worsened by a newly implemented price cut in China.

article source
 




Top Bottom
Back
Quote